Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy.
Adolescent
Adult
Aged
Aged, 80 and over
DNA Mutational Analysis
Drug Resistance, Neoplasm
/ genetics
Female
High-Throughput Nucleotide Sequencing
Humans
Imatinib Mesylate
/ therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Male
Middle Aged
Mutation
Protein Kinase Inhibitors
/ therapeutic use
Young Adult
CML
Fusion gene BCR/ABL
Imatinib resistance
NGS
T315I
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
28 Aug 2021
28 Aug 2021
Historique:
received:
11
06
2021
accepted:
17
08
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
11
1
2022
Statut:
epublish
Résumé
Imatinib mesylate, a tyrosine kinase inhibitor, is the first choice in chronic myeloid leukemia treatment. However, resistance to imatinib may develop with time and in some cases, patients may not respond at all to imatinib. Progressive resistance to imatinib therapy is often due to mutations in the BCR/ABL region. Within the scope of our study 124 patients were evaluated via pyrosequencing between 2015 and 2020. In this regard, 32 patients who have a partial response and have no response to imatinib therapy were included in the study. In addition, next-generation sequencing (NGS) analysis was performed on 15 patients who were resistant to imatinib treatment according to the molecular follow-up reports. With pyrosequencing, 5 cases out of a total of 124 were found to be positive. This means that approximately 4.03% of the proportion is positive. But when we examined only 32 patients who have a partial response and have no response to imatinib therapy this rate is rising 15.6%. NGS analysis was performed with 15 patients who have no mutation with pyrosequencing of 32 patients and VUS (Variant of Uncertain Significance) mutation was detected in one. In this study, our aim was to determine the mutations of the BCR/ABL and to evaluate the mutations by NGS and pyrosequencing. Our study is important in terms of comparing the pyrosequencing with NGS mutation rates, drawing attention to the clinical importance of log reduction.
Identifiants
pubmed: 34453624
doi: 10.1007/s12032-021-01571-1
pii: 10.1007/s12032-021-01571-1
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120Informations de copyright
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Faderl S, Talpaz M, Estrov Z, O’brıen S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164–72.
doi: 10.1056/NEJM199907153410306
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–22.
doi: 10.1182/blood-2013-02-483750
Linev AJ, Ivanov HJ, Zhelyazkov IG, Ivanova H, Goranova-Marinova VS, Stoyanova VK. Mutations associated with imatinib mesylate resistance—review. Folia Med (Plovdiv). 2018;60(4):617–23.
doi: 10.2478/folmed-2018-0030
Izzo B, Gottardi EM, Errichiello S, Daraio F, Baratè C, Galimberti S. Monitoring chronic myeloid leukemia: how molecular tools may drive therapeutic approaches. Front Oncol. 2019;9:1–12.
doi: 10.3389/fonc.2019.00833
Hantschel O. Chronic myeloid leukemia. HemaSphere. 2019;3(S2):47.
doi: 10.1097/HS9.0000000000000254
Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 2007;249(2):121–32.
doi: 10.1016/j.canlet.2006.07.010
Yaghmaie M, Yeung CC. Molecular mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep. 2019;14(5):395–404.
doi: 10.1007/s11899-019-00543-7
Bavaro L, Martelli M, Cavo M, Soverini S. Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update. Int J Mol Sci. 2019;20(24):1–23.
doi: 10.3390/ijms20246141
Etienne G, Dulucq S, Huguet F, Schmitt A, Lascaux A, Hayette S, et al. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors. Cancer Med. 2019;8(11):5173–82.
doi: 10.1002/cam4.2410
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–23.
doi: 10.1038/gim.2015.30
Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, et al. The philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016;35(1):1–15.
doi: 10.1186/s40880-016-0108-0
Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276–83.
doi: 10.1182/blood-2002-09-2896
Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, et al. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. Ann Hematol. 2006;85(12):841–7.
doi: 10.1007/s00277-006-0171-8
Chien SH, Liu HM, Chen PM, Ko PS, Lin JS, Chen YJ, et al. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors. Hematol Oncol. 2020;38(3):390–8.
doi: 10.1002/hon.2721
Baccarani M, Rosti G, Soverini S. Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia. 2019;33(10):2358–64. https://doi.org/10.1038/s41375-019-0562-1 .
doi: 10.1038/s41375-019-0562-1
pubmed: 31455852
Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014;20(2):310–22.
doi: 10.1158/1078-0432.CCR-13-1988
Alikian M, Gale RP, Apperley JF, Foroni L, Alikian M. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomol Detect Quantif. 2017;11:4–20. https://doi.org/10.1016/j.bdq.2017.01.001 .
doi: 10.1016/j.bdq.2017.01.001
pubmed: 28331814
pmcid: 5348117
El Fakih R, Chaudhri N, Alfraih F, Rausch CR, Naqvi K, Jabbour E. Complexity of chronic-phase CML management after failing a second-generation TKI. Leuk Lymphoma. 2019;61(4):776–87.
doi: 10.1080/10428194.2019.1691196
Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141(5):887–99.
doi: 10.1007/s00432-014-1845-6
de Lavallade H, Jackson S, Kizilors A, Etienne G, Huguet F, Guerci-Bresler A, et al. Prospective evaluation of ABL kinase domain mutational analysis by next-generation-sequencing in newly diagnosed CP CML patients undergoing first-line treatment with nilotinib alone or nilotinib + pegylated interferon-α2a in a prospective phase III trial. Blood. 2019;134(Supplement_1):664–664.
doi: 10.1182/blood-2019-125108
Soverini S, Abruzzese E, Bocchia M, Bonifacio M, Galimberti S, Gozzini A, et al. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. J Hematol Oncol. 2019;12(1):1–11.
doi: 10.1186/s13045-018-0686-1
Soverini S, Bavaro L, de Benedittis C, Martelli M, Iurlo A, Orofino N, et al. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood. 2020;135(8):534–41.
doi: 10.1182/blood.2019002969
Soverini S, Martelli M, Bavaro L, De Benedittis C, Papayannidis C, Sartor C, et al. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2021;193(2):271–9.
doi: 10.1111/bjh.17301
Koçkan B, Toptaş T, Atagündüz I, Tuğlular AT, Özer A, Akkiprik M. Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia. Oncol Lett. 2018;15(2):2419–24.
pubmed: 29434953
Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530–42.
doi: 10.1016/j.ccell.2020.03.006
Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018–29.
doi: 10.1016/S1470-2045(07)70342-X
Azad NA, Shah ZA, Pandith AA, Rasool R, Rasool JA, Baba SM, et al. Analysis of ABL kinase domain mutations as a probable cause of imatinib resistance in chronic myeloid leukemia patients of Kashmir. Meta Gene. 2018;17:93–8. https://doi.org/10.1016/j.mgene.2018.05.003 .
doi: 10.1016/j.mgene.2018.05.003
Fojo T. Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updates. 2007;10(1–2):59–67.
doi: 10.1016/j.drup.2007.02.002
Perrotti D, Silvestri G, Stramucci L, Yu J, Trotta R. Cellular and molecular networks in chronic myeloid leukemia: the leukemic stem, progenitor and stromal cell interplay. Curr Drug Targets. 2016;18(4):377–88.
doi: 10.2174/1389450117666160615074120
Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematol Am Soc Hematol Educ Program. 2009;2009:461–76.
doi: 10.1182/asheducation-2009.1.461
Gorre M, Sashidhar R, Annamaneni S, Digumarti R, et al. Demographic and clinical characteristics of chronic myeloid leukemia patients: a study on confined populations of southern India. Indian J Med Paediatr Oncol. 2019;40(1):70–6.